COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,833 Articles (22,553 medRxiv, 8,280 bioRxiv)

Most recent first Previous |  Page 626: Articles 6251-6260  | Next

The Spike protein of SARS-coV2 19B (S) clade mirrors critical features of viral adaptation and coevolution
Hussein, B. K., Ibrahium, O. M., Alamin, M. F., Ahmed, L. A. M., Abuswar, S. A. E., Abdelraheem, M. H., Ibrahim, M. E.
10.1101/2022.08.12.503822 — Posted: 2022-08-15
The P681H mutation in the Spike glycoprotein escapes IFITM restriction and is necessary for type I interferon resistance in the SARS-CoV-2 alpha variant
Lista, M. J., Winstone, H., Wilson, H., Dyer, A., Pickering, S., Galao, R. P., De Lorenzo, G., Cowton, V., Furnon, W., Suarez, N. M., Orton, R., Palmirini, M., Patel, A. H., Snell, L. B., Nebbia, G., Swanson, C. M., Neil, S. J.
10.1101/2022.08.11.503706 — Posted: 2022-08-15
Circulation of respiratory viruses during the COVID-19 pandemic in The Gambia
Jarju, S., Senghore, E., Brotherton, H., Saidykhan, A., Jallow, S., Krubally, E., Sinjanka, E., Ndene, M. N., Bajo, F., Sanyang, M. M., Saidy, B., Bah, A., Forrest, K., Clarke, E., Dalessandro, U., Usuf, E., Cerami, C., Roca, A., Kampmann, B., Silva, T. d.
10.1101/2022.08.08.22278521 — Posted: 2022-08-14
Comparison of antibody responses to SARS-CoV-2 variants in Australian children
Toh, Z. Q., Mazarakis, N., Nguyen, J., Higgins, R. A., Anderson, J., Do, L. A. H., Burgner, D. P., Curtis, N., Steer, A. C., Mulholland, K., Tosif, S., Licciardi, P.
10.1101/2022.08.12.22278705 — Posted: 2022-08-13
Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4 and BA.5 in patients receiving monoclonal antibodies
BRUEL, T., STEFIC, K., NGUYEN, Y., TONIUTTI, D., STAROPOLI, I., PORROT, F., GUIVEL-BENHASSINE, F., BOLLAND, W. H., PLANAS, D., HADJADJ, J., HANDALA, L., PLANCHAIS, C., PROT, M., SIMON-LORIERE, E., ANDRE, E., BAELE, G., CUYPERS, L., MOUTHON, L., MOUQUET, H., BUCHRIESER, J., SEVE, A., PRAZUCK, T., MAES, P., TERRIER, B., HOCQUELOUX, L., SCHWARTZ, O.
10.1101/2022.08.12.22278699 — Posted: 2022-08-13
Safety and Immunogenicity of a Recombinant Protein RBD Fusion Heterodimer Vaccine against SARS-CoV-2: preliminary results of a phase 1-2a dose-escalating, randomized, double-blind clinical trial.
Leal, L., Pich, J., Ferrer, L., Nava, J., Marti-Lluch, R., Esteban, I., Pradenas, E., Raich-Regue, D., Prenafeta, A., Escobar, K., Pastor, C., Ribas-Aulinas, M., Trinite, B., Munoz-Basagoiti, J., Domenech, G., Clotet, B., Corominas, J., Corpes-Comes, A., Garriga, C., Barreiro, A., Izquierdo-Useros, N., Arnaiz, J. A., Soriano, A., Rios, J., Nadal, M., Plana, M., Blanco, J., Prat, T., Torroella, E., Ramos, R.
10.1101/2022.08.09.22278560 — Posted: 2022-08-12
An evaluation of the early impact of the COVID-19 pandemic on Zambia's routine immunization program
Winter, A. K., Takahashi, S., Carcelen, A., Hayford, K., Mutale, W., Mwansa, F. D., Sinyange, N., Ngula, D., Moss, W. J., Mutembo, S.
10.1101/2022.08.12.22278710 — Posted: 2022-08-12
Risk factors for COVID-19 hospitalization or death during the first Omicron surge in adults: a large population-based case-control study
Lo, T., Usman, H., Sikdar, K. C., Strong, D., James, S., Ross, J., Saxinger, L.
10.1101/2022.08.11.22278682 — Posted: 2022-08-12
Estimation of the Total Number of Infected Cases in the 5th Wave of COVID-19 in Hong Kong
Chow, W. K., Chow, C. L., Cheng, C. H.
10.1101/2022.08.12.22278708 — Posted: 2022-08-12
Sphingosine kinases promote Ebola virus infection and can be targeted to inhibit filoviruses, coronaviruses, and arenaviruses using late endocytic trafficking to enter cells
Stewart, C. M., Bo, Y., Fu, K., Chan, M., Kozak, R., Apperley, K. Y.-P., Laroche, G., Beauchemin, A., Kobinger, G., Kobasa, D., Cote, M.
10.1101/2022.08.12.503750 — Posted: 2022-08-12

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).